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Introduction. Cognitive dysfunction as a core feature in the course of bipolar aﬀective disorder (BPD) is a current subject of
debate and represents an important source of psychosocial and functional burden. Objectives. To stand out the connection and
clinical implications between cognitive dysfunction, dementia, and BPD. Methods. A nonsystematic review of all English language
PubMed articles published between 1995 and 2011 using the terms “bipolar disorder,” “cognitive dysfunction,” and “dementia”.
Discussion. As a manifestation of an aﬀective trait or stage, both in the acute phases and in remission, the domains aﬀected include
attention, executive function, and verbal memory. The likely evolution or overlap with the behavioural symptoms of an organic
dementia allows it to be considered as a dementia speciﬁc to BPD. This is named by some authors, as BPD type VI, but others
consider it a form of frontotemporal dementia. It is still not known if this process is neurodevelopmental or neurodegenerative in
nature, or both simultaneously. The assessment should consider the iatrogenic eﬀects of medication, the aﬀective symptoms, and a
neurocognitive evaluation. Conclusion. More speciﬁc neuropsychological tests and functional imaging studies are needed and will
assume an important role in the near future for diagnosis and treatment.
1.Introduction
For a long time mild and severe cognitive deﬁcits have been
recognized as part of mental disorders. In aﬀective disorders,
although initially considered as secondary features related to
social or psychological factors, they are now recognized as
playing an integral part of the clinical expression [1]a n da
connection with dementia has also been suggested [2]. More
than half of patients with prolonged BPD over 60 years have
cognitive deﬁcits [3] and about two-thirds have subjective
amnesic complaints [1].
Yet, the recognition of the impact of these deﬁcits on
psychosocial and occupational functioning [4–6] and ther-
apeutic compliance (patients often attribute these deﬁcits
to medication side eﬀects) is an important feature of BPD
[7]. Also, it certainly contributes to an impairment of
functional recovery, which even in euthymia is achieved
slowly, despite modern symptomatic treatments [7]. In
fact, recent reports have documented that some cognitive
deﬁcits (processing speed and verbal learning/memory) are
independent predictors of functional recovery [6, 8] and also
that improvements in neurocognitive status could predict
changes in functional outcome [9].
The consideration of cognitive impairment as a neurode-
velopmental or neurodegenerative/progressive process is a
controversial issue that remains under discussion today and
the most accepted view is that it is probably a combination
of both etiopathogenic mechanisms. In cases of dementia,2 Depression Research and Treatment
further doubts remain if neurocognitive impairment could
be a marker of progressive decline to a speciﬁc dementia
of BPD, but the coexpression with other types of organic
dementia could also be a possibility. Therefore, it is not
deﬁnitely known whether this is a chance association or if
there is an etiopathogenic link between BPD and dementia
[10].
2.ClinicalFeatures
2.1. Cognitive Dysfunction. In BPD, the cognitive dysfunc-
tion probably has a multifactorial aetiology involving a gene-
environment interaction. There is remarkable interindivid-
ual variability in its clinical functioning [8]. In general, there
are changes in the areas of verbal memory, attention, and to
some extent in executive function and visual memory [11].
Althoughremissionoccursineuthymiainthevisualmemory
and working memory domains, the persistence of the others
may be a marker for progression to a neurodegenerative
process [7, 12]. This is somewhat contrary to the assumption
of Emil Kraepelin that full recovery existed between episodes
in BPD.
In fact, results of recent meta-analytic studies have
documented the existence of cognitive deﬁcits in all phases
of BPD, which are apparently independent of the aﬀective
state [11, 13]. These involve selective attention/processing
speed, concentration, immediate episodic memory, atten-
tional deviance, strategic thinking [7, 12], abstraction, verbal
learning/immediate memory/planning, and perseveration
[1, 11, 13–19]. Also, the deﬁcits in executive function
(initiation of response and inhibitory control) are probably
related to dysfunction of the prefrontal cortex and may be
responsible for reducing the patient’s coping abilities, mak-
ing individuals more vulnerable to recurrence of symptoms
[20]. Notwithstanding, there is relative preservation in the
visuospatial memory, verbal ﬂuency, and vocabulary [21–
23].
In studies of emotional processing, both the perception
of identity and the recognition of facial aﬀection were found
to be preserved in the acute phases or in remission [20].
With regard to social cognition, the studies addressing the
Theory of Mind (ToM, e.g., the ability to represent one’s
own and others’ mental states) have showed that a probable
interaction with other cognitive domains such as attention
or poor executive functioning may be involved [20]. A
recent report, however, concluded that impairment on ToM
is partially independent of dysfunction in other cognitive
domains and the mood state, and even may represent a
trait marker of BPD [24]. Parts of the widespread neural
network involving cortical midline structures in ToM are
in accordance with the neuroanatomical and neuroimaging
ﬁndings, namely, insula, temporoparietal junction, anterior
cingulate cortex, and precuneus [25]. However, the existing
data is still scarce.
2.2. Cognitive Dysfunction in BPD Type I, BPD Type II, and
UnipolarDepression. MoststudiesrefertoBPDtypeI,which
is more associated with verbal memory, visual memory, and
semantic ﬂuency deﬁcits; BPD type II patients, on the other
hand, probably have less widespread and severe cognitive
dysfunction than BPD type I [11]. This is somewhat in
accordance with the association of psychosis or mania events
and more severe impairment in the memory domain, which
is more common in BPD I. In fact, BPD patients with a
past history of psychosis showed more severe deﬁcits in
verbal memory [18, 26, 27] and working memory/executive
function [28] than those without a history. There is an
association between BPD type I patients with a positive
family history of psychotic illness and worse performance
in selective attention and visual-motor processing [29]. A
common pathophysiology in the medial temporal regions to
verbalmemoryandsemanticﬂuencydeﬁcitsforapotentially
speciﬁc endophenotype of BPD type I was proposed [30], in
accordance with neuroimaging ﬁndings [31].
Also, there seem to be diﬀerences in the cognitive deﬁcits
domains related to type of aﬀective state. Mania is associated
with more pronounced deﬁcits in verbal memory and execu-
tive function, while depression is associated (albeit with less
statistical power) with deﬁcits in executive function, verbal
learning, and visual and spatial memory. Interestingly, an
initialepisodeofmaniainearlyages(ratherthanadepressive
episode) was associated with increased risk of late cognitive
dysfunction [4]. Also, in depressive and untreated episodes
(compared with those treated), there are pronounced deﬁcits
in visual recognition of facial expressions and attention [18,
26, 27] and also poorer verbal ﬂuency [32]. It is not known
to date if a more severe proﬁle in BPD type I patients is
due to the neurotoxic eﬀects of manic episodes or due to
neurobiological diﬀerences from the onset of illness.
The cognitive deﬁcits between bipolar and unipolar
depression appear similar, but more severe in the ﬁrst [33]. A
recent study, although with a short sample, also concluded
for similar psychosocial and neurocognitive functioning
among major depressive disorder (MDD) and BPD patients
duringadepressiveepisode,inthecaseofsevereandcomplex
mood disorders [34].
Apparently, there is a positive association between psy-
chotic symptoms, age of onset (the number of aﬀective
episodes associated with decreased motor speed and execu-
tive function) [35], and duration of the disease (associated
with decreased verbal memory) [4, 18] with severity of
cognitive deﬁcits [19] and also with the risk of a diagnosis
of dementia [22]. An association to environmental factors,
namely, obstetric complications, infection with herpes sim-
plex virus type 1 (HSV-1), and early traumatic adversity was
also documented [36].
It is generally agreed that BPD is pleomorphic, with
individual heterogeneous presentations and diﬀerent out-
comes. Some patients experience a worse clinical course
from the beginning, while others have good interepisodic
functional recoveries despite multiple recurrences. Notwith-
standing, there are still doubts whether a poorer course
is the consequence of cognitive deﬁcits, which is more
unfavourable than previously thought and whether this is
stable and developmental or neurodegenerative/progressive
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Progressive and stage-related neuroanatomical changes
and cognitive decline are in concordance with progressive
biochemical changes [38]. These occur not only in the well-
documented monoamine and second messenger abnormal-
ities but also in inﬂammatory cytokines, corticosteroids,
neurotrophins, mitochondrial energy generation, oxidative
stress, and neurogenesis [39]. Taking into account this pro-
gressivenatureofBPD,knownasneuroprogression,astaging
model for BPD was proposed by Berck and collaborators
[40, 41]. In this model, the clinical stage is based on the
assumption that in earlier stages of the disease, as opposed
to chronic ones, there are better prognosis and better
response to treatment [40]. This can also be viewed as a
course speciﬁer, in which an early diagnosis and intervention
seems tangential with the parallel notion of neuroprotection
[13, 38]. The progressive nature of evolution of BPD
could therefore be reversible with the appropriate algorithm
treatment comprising this neuroprotective measure and/or
novel agents [38, 40]. Furthermore, progressive shortening
of the inter-episodic interval, cognitive impairment and
higherratesofphysicalcomorbidityandmortalityduringthe
course of BPD are in accordance with reduced probability
of treatment response [38]. This highlights the importance
of eﬀective long-term prophylaxis, because it seems that
resilience decreases with the cumulative eﬀects of chronic
stress and intermittent episodes. This eﬀect was proposed
as the allostatic load in BPD, in which recurrent stress
induces abnormalities in the brain that lead to changes
in processing information [42]. Consequently, a greater
number of recurrent episodes and stressors make patients
more vulnerable or less resilient to subsequent episodes or
stressors [43].
Although it seems that cognitive functioning deterio-
rates over time with disease progression and worsens with
repeated acute episodes, there are few longitudinal studies
addressing the neurocognitive function and outcome. The
ﬁndings of a prospective longitudinal study over 3 years to
investigate the stability and speciﬁcity of cognitive impair-
ment in BPD type I, after controlling for age and length
of illness, suggest this is mainly stable over time [44]. But,
in a follow-up study over 15 years, cognitive dysfunction,
namelyinprocessingspeedandverballearningdomains,was
independently associated with social and global functioning
outcome in BPD [6]. The diﬀerent nature of both processes
could rather explain the diﬀerences between BPD type I
a n dt y p eI In e u r o c o g n i t i v ep r o ﬁ l e[ 30]. Although it seems
that cognitive deﬁcits are present in the ﬁrst episode [45],
there is a lack of studies of premorbid functioning evaluating
possible alterations that occurred before the establishment of
the disorder.
2.3. A Speciﬁc Dementia of BPD? This topic is currently
under discussion and some authors have suggested diﬀerent
views. Akiskal and colleagues suggest a particular form of
late-onset of BPD in the elderly, accompanied by cognitive
dysfunction, named by the authors as BPD type VI, in
previously healthy individuals. According to these authors
there is a concomitant clinical interface of mood instability,
irritability and aggression with disturbance of memory and
other cognitive deﬁcits in an early onset of dementia [46].
Thus, nonspeciﬁc behavioural symptoms of dementia can
be an expression with an aﬀective episode of a co-morbid
undiagnosed BPD, or otherwise to promote the expression
of latent bipolarity [46, 47]. For another perspective, a
pre-existing BPD undiagnosed can also be postulated as
contributing to the symptoms of aﬀective dysregulation of
dementia [48]. This is an important perspective to consider
as BPD represents approximately 20% of mood disorders
in the elderly [49] and 8% of new cases of BPD occur in
geriatric patients [50]. Also, the spectrum of BPDs in the
general population is 5.4 to 8.3% [51], so a high number of
patients will remain without a diagnosis.
So, the hypothesis of the coexistence of an organic
dementia and a bipolar spectrum disorder represents an
alternative to the neurological clinical view that agita-
tion, impulsivity and mood instability of dementia are
an expression of frontal lobe dysfunction [52]. In fact,
the psychopathological similarities between the behavioural
manifestations of dementia and aﬀective episodes of BPD
have become a real clinical challenge for their diagnosis
and proper treatment. Low social engagement, fatigue and
lack of initiative can be present in a depressive state and
can be common between the two entities, a situation that
can lead to diagnostic confusion. Disorders of the sleep-
wake cycle and delusional activity of similar types are
common in both entities. Thus, an inappropriate motor
behaviour in dementia can be a form of disorganized
hyperactivity of BPD. Denial and anosognosia of dementia
can be understood as the omnipotence of mania, and
expensive spending of mania can be interpreted as an altered
behaviour of dementia. Familiarity, joy and loss of social
conformity can be a component of frontal dysfunction and
also be secondary to the elation of humour. In fact, the
evidence of relative similarity with frontal lobe dysfunction,
documented in changes of personality, apathy and social
disability in addition to the type of cognitive domains
involved and neuroimaging ﬁndings (see next section) has
led some authors to propose the dementia of BPD as a form
of clinical presentation of a frontal-subcortical dementia
(frontotemporal dementia-FTD) [53]. Besides that, there
seem to be diﬀerences in the frontal signs, observed by
less self-neglect and less emotional indiﬀerence and also
diﬀerencesrelatedtooutcomeandprognosis[53].Apossible
pathological connection process between schizophrenia and
BPD reported in a series of cases of FTD supports the
hypothesis of these two pathologies being linked in the
same cerebral region. Additionally, it suggests a subgroup
within the frontotemporal lobar degeneration connected to
the outcome of dementia in some bipolar patients [54].
Interestingly, psychiatric symptoms can be a prodrome or
an independent risk factor in patients who go on to develop
neurodegenerative disease (ND). A recent study involving
252 patients in a speciality clinic, 28,2% with a diagnostic
ND, received a prior psychiatric diagnosis. The patients
with the behaviour variant frontotemporal dementia were
at the highest risk to misdiagnosis (52.2%) and were more
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the other dementia groups. This was positively associated
with a younger age, higher education, and a family history
of psychiatric illness [55]. The signiﬁcant symptom overlap
betweendementiaandprimarypsychiatricdisordersisapar-
ticular diagnostic challenge. It remains, however, diﬃcult to
establish the true nature of these dementia disorders despite
data emerging from neuropsychological and neuroimaging
studies.
2.4. Genetic Studies. Mutations in genes related to migration
and neurodevelopment were identiﬁed in a subgroup of
bipolar and schizophrenic patients, which predicted the
seriousness of prefrontal cognitive deﬁcits in both disorders.
Also, a developmental delay in verbal memory and executive
domainswasdemonstratedinpaediatricBPD[56].However,
most appear to ﬁt into a neurodegenerative model, which
further contributes to medical comorbidities, impaired psy-
chosocial functioning, the number of episodes, and biologi-
cal changes [42]. Also, polymorphisms in brain-derived neu-
rotrophic factor and cathecol O-methyltransferase (COMT)
were associated with abnormal cognitive function [57, 58].
An additive gene-environment eﬀect has been documented
with polymorphisms of COMT and seropositivity to HSV-1
[59].
Infamilystudies,deﬁcitsinexecutivefunctionandverbal
memory [22] and also cognitive ﬂexibility and attentional
shift[21]weredemonstratedinhealthysiblings.Thefactthat
theyareverysimilartothosedescribedintheeuthymicphase
suggests that they may be genetic vulnerability markers or
traits, again supporting the neurodevelopmental hypothesis.
Also, some cognitive deﬁcits appear to be inﬂuenced by
the same genes that predispose to illness [60]. But that
fact is not entirely clear, since there are no conclusive
prospective studies to assert which and in what gravity (or
risk-enhancing factors) can be predictors to development of
diﬀerent types of aﬀective disorders [61] and their impact on
functional status.
2.5. Neurochemical, Neurophysiological, Neuroanatomical,
and Neuroimaging Studies. High concentrations of regional
brain monoamine substances [62], abnormally increased
glucocorticoid receptor function [63], and high concentra-
tions of homocysteine [64] were found in neurochemical
studies. In euthymic patients an increase in amplitude of
waves was found on electroencephalogram, especially in
brain areas associated with visuospatial processing deﬁcit
[65].
As occurred in unipolar depression, cognitive deﬁcits
may be related to structural brain abnormalities, and several
studies have found that the latter can probably be predictors
of their development and/or even of dementia [1]. It was
reported that patients with BPD could have brain tissue loss,
although the speed of grey matter loss was slow and well
correlated with the deterioration of cognitive function and
mood episodes [66].
The changes of parenchyma seem not to be pervasive
but region speciﬁc. In fact, the most signiﬁcant ones refer
to increase in the hippocampus and in amygdala volume,
mild ventricular enlargement (predominant in the right
lateral ventricle), and changes in association cortex (pre-
frontal cortex, anterior cingulate and dorsolateral prefrontal
nucleus) [67]. Importantly, the changes at the level of the
cingulatecortex(atrophyoffrontalandtemporallobes)seem
to predispose to frontal and temporal circuit dysfunction.
This is in accordance with predominant hypoperfusion at
frontotemporal regions observed in studies of functional
neuroimaging [67]. In a recent quantitative meta-analysis
of functional magnetic ressonance imaging (fMRI) studies
in BPD, there was abnormal frontal-limbic activation [68].
This was manifested by underactivation of the inferior
frontal cortex or ventrolateral prefrontal cortex (consistent
across emotional and cognitive tasks and particularly related
to the state of mania) and overactivation of limbic areas
(including medial temporal structures: parahippocampal
gyrus, hippocampus, and amygdala) and basal ganglia [68].
These last were elicited by emotional but not cognitive tasks
and also not clearly related to mood states [68]. This is
somewhat in corroboration with the ﬁndings of a recent
investigation using diﬀusion tensor tractography in BPD
patients which found speciﬁc white matter ﬁber bundle
abnormalities and disrupted integrity connecting structures
of the anterior limbic network [69].
Also, studies with brain MRI revealed the existence
of white matter hyperdensity of periventricular and deep
subcortical location associated with cognitive deﬁcits in pro-
longed illness and also with a poor prognosis [70]. However,
white matter lesions in euthymic patients with cognitive
impairment did not diﬀer from asymptomatic controls [71].
The lack of alterations in cerebral morphology in elderly
euthymic BPD patients could suggest either a progressive
neurotoxic process [72]. Again, because abnormalities in
volume of the amygdala have been found similar in both
children and adults, and also in patients with ﬁrst or
multiple episodes, functional neuroanatomical deﬁcits do
not necessarily reﬂect a neurodegenerative process [42].
3. Evaluation
3.1. General Aspects. The rigorous evaluation of cognitive
deﬁcits apparent on clinical examination in BPD requires a
systematic approach to psychiatric and medical comorbidi-
ties, iatrogenic eﬀects, and a neuropsychological evaluation.
Firstly it is necessary to consider the patient’s age (inde-
pendent risk factor) as well as the intelligence quotient and
premorbid level of education. Compared with BPD adult
patients, geriatric BPD patients have a similar pattern of
cognitive dysfunction, but children with BPD [73] show the
greatest eﬀects in verbal memory and the smallest diﬀerences
in motor speed and intelligence [74].
In cases of dementia where there is a suspicion of an
unrecognized bipolar spectrum disorder, the diﬃculty in
the evaluation makes help from family a valuable way of
getting information. Prior psychiatric history (episodes of
mania and/or depression, suicide attempts, anxiety disor-
ders, alcoholism, and substance abuse), previous personality
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[46, 47], and life-events (disturbances in interpersonal rela-
tionships, unemployment, etc.) are important elements that
should be addressed in the history assessment. Premorbid
personality described as energetic and prone to hyperactivity
[46] and a positive family history of BPD are important
associations in patients with comorbid dementia and late-
onset BPD [47, 48].
3.2. Psychiatric and Medical Comorbidities. Anxiety disorder,
obsessive compulsive disorder, dissociative disorder, sub-
stance abuse disorder, and other aspects of psychopathology
are often comorbid with BPD [75]. Its evaluation becomes
important because changes in these psychopathological
states can alter cognitive functions such attention and
processing speed [11, 76]. Also, a positive association of
severecognitivedysfunctionwithdiabetes[4]andotherhigh
prevalent medical comorbidities such as cerebrovascular
disease in this population has been documented (24% in
long-term illness have two or more risk factors) [77].
3.3. Iatrogenic Eﬀects. Cognition can be modiﬁed by iatro-
genic or drug interactions often inherent in polypharmacy
[36, 78]. As a potential aggravating and confounding factor,
this is important to take into account in view of avoiding
untimely antidementia prescription, instead of reduction,
replacement, or elimination of drugs that may be the cause
of such symptoms.
The use of mood stabilizers requires an analysis of
risk/beneﬁt. Changes in cognitive function secondary to
the use of lithium are well documented in healthy subjects
and euthymic patients and are independent of the disease.
Reduction of short-term memory, motor function, verbal
associative ﬂuency, and attention [11]i sd o c u m e n t e da n d
patients typically report feeling of dullness and decreased
cognitive creativity. Hypothyroidism resulting from chronic
use of this drug may also be associated with apathy and
cognitive deﬁcits.
The range of cognitive deﬁcits expected with the use of
other mood stabilizers is diverse being virtually absent with
lamotrigine and gabapentin [79–81]. These are relatively
modest and transient (in learning and memory domains)
with sodium valproate and carbamazepine. A diﬀuse eﬀect
particularly in attention, verbal memory, psychomotor retar-
dation, and diﬃculties in the recall of words is documented
with topiramate [82, 83].
Most studies addressing cognitive function with antipsy-
chotics refer to schizophrenia and, in BPD, apart of being
scarce, were carried out in a small number of patients.
However, there is documented adverse eﬀects at the level
of planning tasks and processing speed [84], and also on
executive function [85]. Despite inconsistencies, the use of
benzodiazepines is associated with problems in working
memory and processing speed, and its prolonged use could
confound neuropsychological assessment [86]. Antidepres-
sants, with the exception for anticholinergic eﬀects of
tricyclics [87] do not have important documented adverse
cognitive eﬀects, and, on the contrary, recent evidence shows
thatserotoninmayhaveapositiveeﬀectonworkingmemory
[88].
3.4. Neuropsychological Evaluation. Given the heterogeneity
of clinical expression of cognitive dysfunction in BPD, it
is necessary to carry out a thorough neuropsychological
evaluation.AlongwiththeMinimentalStateofExamination,
it must include tests that analyse the domains of attention,
memory, and executive function, among others [11]. There
isnotatpresentabatteryofneuropsychologicaltestsadapted
and validated for BPD. This will be an important support
to the clinical decision on treatment, rehabilitation, and
restoration of functional capacity adapted to the real world
in the future [89]. Moreover, it is an important vehicle for
investigation of neuroanatomical and functional changes,
geneticphenotypes,andexpressionofsymptomsandclinical
beneﬁts or disadvantages of treatment.
The promising results of a battery of cognitive tests
for clinical research in the area of cognitive dysfunction
in schizophrenia (measurement and treatment research to
improve cognition in schizophrenia: MATRICS Consensus
Cognitive Battery, MCCB) [90–92] recently served as a
model for research in cognitive assessment in BPD [20].
This initiative promoted by the International Society for
Bipolar Disorders intended to identify in the literature the
cognitive tests included in the MCCB best adapted to BPD,
taking into account the fact that cognitive deﬁcits are similar
in pattern but less severe than in schizophrenia [11]a n d
also the overlapping aspects of neurobiology, genetics, risk
factors, and neuropsychological functioning. This investi-
gation concluded that the tests included in the MCCB
(concerning processing speed, attention/vigilance, working
memory, verbal learning, visual learning, executive function,
and social cognition) should be complemented by more
complextestsatthelevelofverballearning(CaliforniaVerbal
Learning Test) and executive function (Stroop Test, Trail
Making Test—part B, Wisconsin Card Sorting Test) [20].
Also, it will include speciﬁc tests for emotional processing
and social cognition of BPD [20]. This is in accordance
with the results of a recent study using the MCCB in BPD
type I patients, where a statistically signiﬁcant impairment
was veriﬁed in ﬁve of seven MCCB domains, but in less
impairment on the reasoning and problem-solving and
social cognition domains [93]. Nevertheless, and although
more studies are needed to test for repeatability, this may be
a feasible instrument in cognitive trails for BPD [93].
4. Treatment
Treatment of cognitive dysfunction in BPD requires the
determination of speciﬁc cognitive deﬁcits, aiming its eti-
ological origin [11] and the thymic stabilization of the
disorder [36]. The lack of speciﬁc pharmacological therapy
that can substantially improve the cognitive symptoms
remains currently under investigation, but drugs with a
favourable or neutral cognitive proﬁle are advisable.6 Depression Research and Treatment
The treatment of behavioural and psychological symp-
toms of dementia and a possible concomitant bipolar spec-
trum disorder should be more focused on mood stabilizers
than antidepressants. This is because of antidepressants’
iatrogenic eﬀects inducing conversion to excitability, hypo-
mania, or mania. In the context of dementia this elation
of mood can be expressed by a worsening of behavioural
and psychological symptoms. Apparently, antidepressants
may be refractory and even worsen behavioural symptoms
[47]. Thus, the onset of agitation in dementia, after use of
antidepressants, should assume the investigation of a bipolar
spectrum disorder.
Evidence of use of mood stabilizers on BPD in the elderly
is scarce [94], and in general, the maximum doses are lower
and require a slower titration. Lithium is rarely prescribed
for the ﬁrst time after the age of 70 because of its narrow
therapeutic index and greater risk of neurotoxicity and other
side eﬀects with age [48, 95]. However, neuroprotective
eﬀects of mood stabilizers, as opposed to chronic stress in
neurons, are also described [96]. As they can also have a role
in reducing the number of recurrences, these are indirect
ways of preventing dementia [49].
The eﬀectiveness of sodium valproate, in addition to
being better tolerated than carbamazepine, is well docu-
mented in the treatment of behavioural and psychological
symptoms of dementia and also in behavioural and sleep
disturbances in patients with mania [97, 98]. Dorey and
collaborators have proposed the valproate as the mood
stabilizerofchoice[48]withagradualdosetitrationofabout
125–250mg/day to a maximum dose of 500–1000mg/day
[94]. Antipsychotics may be considered only in situations
of agitation associated with another mood stabilizer [99],
and although there is evidence of beneﬁt [47], its use
requires caution and is even contraindicated in most cases
of dementia.
The utility of procholinergic drugs (donepezil, galan-
tamine, rivastigmine) in behavioural symptoms of dementia
is well documented. Their probable usefulness in cognitive
dysfunction is related to their action on rostral and basal
cholinergic forebrain pathways and in the frontal-striatal
dopaminergic tone. Therefore they may have a role in atten-
tion, working memory [100], and information processing
[101]. Only modest improvement of memory was veriﬁed
in AD, and in schizophrenia, it did not have demonstrable
beneﬁts [102, 103]. In BPD, in particular, despite the limited
and reduced number of studies available, improvement was
veriﬁed with donepezil [104], and possible cognitive beneﬁts
with galantamine [105, 106]. Notwithstanding, as cases of
mania in patients with dementia and comorbid BPD have
been reported in literature with their utilization, caution
with its use should be observed [107].
Relative to antiglutamate agents, data available refers
particularly to schizophrenia, and although the majority
(memantine, d-cycloserine, and glycine) had no beneﬁt over
placebo [108, 109], there is evidence of improvement in
executive function and in global cognitive functioning with
d-serine [110]. However, one study showed potential eﬃcacy
of memantine in the improvement of global cognitive
function, although with a reduced sample [111].
Another area of research is focused in understanding
the aetiology of hypercortisolism associated with mood
disturbances,whichjustiﬁestheinterestintheglucocorticoid
receptor antagonists. In fact, the use of mifepristone (RU-
486), 600mg/day, in patients with BPD was associated
with improvement in spatial working memory, verbal ﬂu-
ency, spatial recognition memory, and depressive symptoms
(although in a small number of participants) [112].
Psychostimulants(amphetamine,methylphenidate)seem
to be potentially attractive in the syndrome of attention
deﬁcit and hyperactivity, apathy of MDD, Parkinson’s dis-
ease, craneoencefalic trauma, and apathy of AD [113]. How-
ever, the available data is scarce, and it is necessary to meet
its side eﬀects [114].
Modaﬁnil may be also a wake-promoting agent to be
taken into account in the future since its use was associated
with improvement in attention, memory, executive function,
visualmemory,andrecentverbalimmediaterecallinchronic
schizophrenia [11, 115].
The potential use of antiparkinsonian drugs such as
pramipexole, pergolide, ropinirole, bromocriptine, and
amantadine results of the D2/D3 agonist eﬀects at the frontal
lobe and consequently on the level of executive processing.
In fact, there was an improvement of cognitive function in
a study using amantadine and pergolide in healthy subjects,
and in another study using pramipexole added to mood
stabilizingagentsinthecontextoftreatmentofthedepressive
phase of BPD patients [116].
The usefulness of antioxidants such as L-Carnosine has
been advocated in the prevention of formation of free
radicals in lipid peroxidation of the neuronal membrane
and excitoxicity of glutamate. These adverse eﬀects on BPD
originate a reduced neuronal viability (documented by a
reduction in more than 40% of the enzyme glutamate
decarboxylase and the enzyme superoxide dismutase within
the hippocampus, and increased toxic activity of gluta-
mate in the synaptic clefts in mania episodes) [117]. The
identiﬁcation of progressive oxidative, inﬂammatory, and
neurotrophic abnormalities associated in parallel with stage-
related structural and neurocognitive alterations advocates
the development of novel treatment classes with a neuropro-
tective eﬀect [39].
T h en o n p h a r m a c o l o g i c a ls t r a t e g i e ss h o u l db ed e ﬁ n e d
by a regular follow-up and monitoring of aﬀective and
cognitive symptomatology and the therapeutic instituted, in
a collaborative eﬀort of the various specialties involved (gen-
eral medicine, neurology, and psychiatry). Prevention and
treatment of cerebrovascular risk factors, particularly with
changing lifestyles such as exercise and healthy diet including
vitamins and mineral supplements, become equally essential
in the treatment process.
It is becoming essential to carry out systematic studies of
strategies of psychotherapy addressing cognitive dysfunction
on BPD [95], as well as cognitive training and rehabilitative
strategies in cognitive domains most predictive of long-
term functional outcome. There is in the last ﬁeld a
nonrandomized pilot study utilizing cognitive remediation
showing some improvements in executive functioning [118].Depression Research and Treatment 7
5. Conclusions
Cognitive dysfunction and dementia associated with BPD
is still a subject little studied. It is related to psychosocial
and functional impairment and also to lower treatment
compliance, representing an important therapeutic target in
the future.
The identiﬁcation of speciﬁc cognitive deﬁcits in the
domains of attention, verbal memory, learning, and exec-
utive functions both during acute stages and in clinical
remission has become important in the clinical approach,
but there is still a lack of a relationship between cognitive
function and psychosocial outcome across illness phases.
A neurodegenerative and/or neurodevelopmental process
involving genetic and environmental risk factors probably
combines to play a role and further studies are needed to elu-
cidate this process. The determination of a speciﬁc dementia
in BPD, with a neuropsychological and imaging proﬁle
similar to, but with better outcomes than an FTD dementia
type, needs to be clariﬁed. In this context, a detailed clinical
history of bipolar traits (premorbid personality, psychiatric
and family history) is useful to their diﬀerential diagnosis,
butevenachanceassociationbetweenthetwoentitiescannot
be excluded.
In this sense, it is imperative to promote further research
in order to obtain instruments for neuropsychological
evaluation speciﬁcally targeted for the diagnosis, to the best
understandingofthenatureandseverityofcognitivedeﬁcits.
A subsequent diﬀerentiation of bipolar subgroups, especially
concerning psychotic symptoms, along with their neuropsy-
chological proﬁle could be important in the establishment
of the outcome, which is still to be determined as stable or
progressive. The importance of development of preventive
strategies and proper treatment could be used in modifying
the prognosis of the disease and in the improvement of
functional recovery rates.
On the other hand, further studies are needed to clarify
the extent of negative side eﬀects of psychotropic drugs
on cognition and assessment of its risk/beneﬁt ratio and
also its relationship with psychosocial functioning. Notwith-
standing, the clinician should be aware of the drugs with
better cognitive proﬁle as well as the eﬀective treatments
for comorbid conditions. Although there is currently no
speciﬁc pharmacotherapy target to cognitive dysfunction
in patients with BPD, new agents such as modaﬁnil or
mifepristone constitute potential options for the future.
The worsening of behavioural symptoms with the use of
antidepressants in situations of coexistence of BPD and
dementia reorients treatment strategies particularly for the
use of mood stabilizers.
The authors expect with this work to have made
a contribution in understanding the connection between
dementia and BPD, which, in the light of present knowledge,
needs to be further investigated with prospective studies and
functional imaging.
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